Focus Partners Wealth
VINC

Focus Partners Wealth’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Focus Partners Wealth’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-545
Closed -$2.87K – 2061
2024
Q4 		$2.87K Buy
+545
New +$3.58K ﹤0.01% 1873
2024
Q3 		– Sell
-545
Closed -$8K – 1733
2024
Q2 		$8K Hold
545
– – ﹤0.01% 1229
2024
Q1 		$10K Buy
+545
New +$34.4K ﹤0.01% 979

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Focus Partners Wealth's VINC Position: Q1 2025 in Review

Focus Partners Wealth sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 545 shares — an estimated $2.87K sold.

Focus Partners Wealth first reported a position in VINC in Q1 2024 and held it in 3 quarters. The position peaked at $10K in Q1 2024. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

  • Focus Partners Wealth reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 545 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $2.87K.
  • Focus Partners Wealth first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2024 and held it in 3 quarters.
  • Focus Partners Wealth's Vincerx Pharma, Inc. Common Stock position peaked at $10K in Q1 2024.
  • 14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Focus Partners Wealth's 13F filing for Q1 2025, filed 15 May 2025.